A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

NCT02337738 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

404

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: TVP-1012 1mg
DRUG: TVP-1012 0.5mg
DRUG: Placebo

Sponsor

Takeda